Novo Nordisk Sees Sales Plummet as Trump's Weight Loss Drug Price Push Takes Toll.
The Danish pharmaceutical giant behind popular weight loss medication Wegovy is now expecting its sales to slump by as much as 13% this year, marking a drastic reversal from years of double-digit growth. This sharp decline comes on the heels of US President Donald Trump's efforts to slash prices for weight loss and diabetes medications.
In an effort to make these expensive treatments more affordable, Novo Nordisk agreed with the Trump administration to lower the cost of its drugs by nearly 50%. While this move may have helped reduce costs for consumers, it has had a devastating impact on the company's bottom line. As a result, Novo Nordisk now anticipates a painful year in terms of revenue.
In contrast, Eli Lilly, another US-based pharmaceutical giant, has forecast stronger-than-expected sales and profit growth for this year. The company credits its product Mounjaro, which leads to greater weight loss in clinical studies, for its expected success.
Despite the challenges facing Novo Nordisk, the company remains optimistic about its future prospects. CEO Mike Doustdar hopes that the current pricing pressure will be an "investment for our future" as it sells higher volumes of obesity and diabetes drugs over the coming years.
However, this prediction appears to be at odds with the disappointing forecast from rival GSK, which has slowed sales growth forecasts due to price cuts in its deals with the Trump administration.
The Danish pharmaceutical giant behind popular weight loss medication Wegovy is now expecting its sales to slump by as much as 13% this year, marking a drastic reversal from years of double-digit growth. This sharp decline comes on the heels of US President Donald Trump's efforts to slash prices for weight loss and diabetes medications.
In an effort to make these expensive treatments more affordable, Novo Nordisk agreed with the Trump administration to lower the cost of its drugs by nearly 50%. While this move may have helped reduce costs for consumers, it has had a devastating impact on the company's bottom line. As a result, Novo Nordisk now anticipates a painful year in terms of revenue.
In contrast, Eli Lilly, another US-based pharmaceutical giant, has forecast stronger-than-expected sales and profit growth for this year. The company credits its product Mounjaro, which leads to greater weight loss in clinical studies, for its expected success.
Despite the challenges facing Novo Nordisk, the company remains optimistic about its future prospects. CEO Mike Doustdar hopes that the current pricing pressure will be an "investment for our future" as it sells higher volumes of obesity and diabetes drugs over the coming years.
However, this prediction appears to be at odds with the disappointing forecast from rival GSK, which has slowed sales growth forecasts due to price cuts in its deals with the Trump administration.
. I mean, it sounds like they're trying to spin this as a "long-term investment", but come on, who wants to invest in a company when you can see the numbers tanking right now? 
It's also interesting that Eli Lilly is doing so well while Novo Nordisk struggles - are they getting some inside info that we don't know about? 
And what's up with GSK slumping their sales growth forecasts too? This whole pricing pressure thing just seems to be a mess 
.
I cant believe trump's weight loss drug push is literally KILLING NOVO NORDISK'S SALES!!! 
they're expecting a 13% SLUMP and it just goes to show how much pressure these big pharma companies are under now. its all about making the meds more affordable, but what about the bottom line?! 
, and now they're basically bleeding cash every quarter 
. Meanwhile, Eli Lilly is over here raking in the dough 
because their product is actually good at helping people lose weight. It's all about the innovation, right? GSK's slowing down sales growth forecasts sounds like a harsh reality check, but Novo Nordisk's CEO seems optimistic about the future... yeah sure 
. I guess we'll just have to wait and see if they can turn that pricing pressure into a "future investment" 
.
. And now I'm seeing Eli Lilly making waves with Mounjaro - that stuff must be doing some serious damage to weight loss 
.
.
. That's a pretty sketchy plan to me. I mean, what if people just avoid these meds altogether because they're too expensive? Or worse, what if they start using less effective treatments because they can't afford the good stuff 
?
. These companies are making billions off people's health problems; it's time for them to take a step back and prioritize people's well-being over profits 
. I mean, yeah, making meds more affordable is great and all, but can't we find a way to make it work for everyone? Not just the companies that are struggling 
? I mean, Mounjaro does seem like a game-changer, but still... Can't we get some consistency here? 
but at the same time, you can't blame trump for trying to make these meds more affordable 
! One minute Novo Nordisk is raking it in and the next they're expecting a 13% slump? What's really going on here? It looks like Trump's weight loss push was just a smokescreen to distract us from something bigger... maybe even a conspiracy to control our waistlines and sell more of their meds 
.
. and yeah, i can see how pricing pressure would be a "investment" 4 their future or watever 
. but gsk is like the opposite lol slowed sales growth. anywayz, gotta keep an eye on Novo Nordisk 
Why do pharmaceuticals have to be so expensive all the time? It's like they're trying to make us suffer through weight loss struggles or whatever. And what's up with Novo Nordisk expecting a 13% sales slump? That's just devastating